Canadas Drug Agency Recommends Funding Lecanemab for Early-Stage...

Compartió un vínculo

2026-07-16 17:00:08

Canadas Drug Agency Recommends Funding Lecanemab for Early-Stage Alzheimers Disease

Lecanemab is shown in this handout photo. Lecanemab is an antibody that targets the buildup of amyloid plaque in the brain, which is believed to be an underlying cause of Alzheimer's disease. The Canadian

0 Commentarios 0 Acciones 14 Views